Gilead Sciences (GILD) Stock Price & AI Analysis

$96.91
-$1.25
(1.27%)
Biotechnology

NASDAQ USA

May 12, 9:37 PM EDT
  • Market Cap.
    120.55B
  • Volume
    13.01M
  • Avg. Volume
    9.78M
  • Target Price
    $116.05
  • 52W Range
    62.07 - 119.96
  • RSI (14)
    34.47
  • Beta
    0.3
  • PEG Ratio
    0.79
  • SMA 20
    -6.34%
  • SMA 50
    -10.17%
  • SMA 200
    3.95%
  • Insider Owner
    0.2%
  • Insider Trans
    -22.83%
  • Institution Owner
    86.88%
  • Institution Trans
    0.65%
  • Short Interest
    23.57%
  • EPS next Y
    6.63

Gilead Sciences Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences | Latest news

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in...

StockStory - 11 hours ago

Gilead Sciences Up Nearly 8%, on Track for Largest Percent Increase Since June...

Gilead Sciences, Inc. (GILD) is currently at $104.56, up $7.66 or 7.9% --Would be highest close since April 30, 2025, when it closed at $106.54 --On pace for largest percent increase since June 20, 2024, when it rose 8.46% --

Morningstar - 4 hours ago

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance...

Insider Monkey - 1 day ago

Pope Leo XIV just took the top job in the Catholic Church—and the role comes...

The first American pope could earn just as much as a U.S. president, but he’ll also enjoy a gilded...

Fortune - 3 days ago

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land &...

Stocks recently featured in the blog include: The Walt Disney Co. DIS, Gilead Sciences, Inc. GILD,...

Zacks - 7 hours ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade...

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P...

StockStory - 3 hours ago

Analysts Issue Forecasts for Gilead Sciences Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Equities researchers at Zacks Research increased their Q2 2025 EPS estimates for Gilead Sciences in a research report issued on Thursday, ...

ETF DAILY NEWS - 19 hours ago

Surprise! Bella Hadid, Queen of Cannes, Is Blonde

While Bella Hadid skipped out on the 2025 Met Gala, all eyes have been primed to see her step out on the Cannes Film Festival red carpet. Famously, it’s...

Vogue - 3 hours ago

Prince William's relatable parenting nightmare after Prince George and Princess...

Credit: Getty Images Prince William gave hope to parents everywhere when he revealed even future...

Woman Home - 10 hours ago

Broadway and ‘Gilded Age’ star Kelli O’Hara is coming to Hampton Roads

Kelli O’Hara is a true star of the stage. A go-to for directors in search of a leading lady, she has...

The Virginian-Pilot - 1 day ago